Posterior Segment Company Showcase - Alimera Sciences
â˘Als PPTX, PDF herunterladenâ˘
1 gefällt mirâ˘421 views
Posterior Segment Company Showcase - Alimera Sciences at OIS@AAO 2016. Presenter: Dan Myers, CEO Powered by: Healthegy For more ophthalmology innovation Visit us at www.ois.net
Empfohlen
Empfohlen
Weitere ähnliche Inhalte
Was ist angesagt?
Was ist angesagt? (20)
Andere mochten auch
Andere mochten auch (20)
Ăhnlich wie Posterior Segment Company Showcase - Alimera Sciences
Ăhnlich wie Posterior Segment Company Showcase - Alimera Sciences (20)
Mehr von Healthegy
Mehr von Healthegy (20)
KĂźrzlich hochgeladen
KĂźrzlich hochgeladen (20)
Posterior Segment Company Showcase - Alimera Sciences
- 1. Investor Presentation January 2015 OIS Meeting October 2016
- 2. Hypertension Daily systemic doses Diabetes Insulin Pump Arthritis Therapy, exercise and at home medication How Chronic Diseases are Treated Today Low patient burden, continuous treatment Bolus injections that last for 1- 3 months administered directly to the eye by a physician, with reinjection every 1-3 months. Ophthalmologists have adopted a standard of care that is inconsistent with the way their fellow physicians in other disciplines treat chronic diseases because their options have been limited. How DME is Treated Today High patient burden, intermittent treatment 22 Š 2016 Alimera Sciences, All Rights Reserved2
- 3. 33 Š 2016 Alimera Sciences, All Rights Reserved3 ILUVIEN is the only therapy that allows physicians to consistently treat DME daily
- 4. Innovative Delivery 44 Š 2016 Alimera Sciences, All Rights Reserved4
- 5. Key DME Management Goals 55 Š 2016 Alimera Sciences, All Rights Reserved5 A dry macula Preservation of vision &/or improving sight Reduction in patient burden 1 2 3
- 6. Consistent Delivery With Sustained Effect ILUVIENŽ Delivers Consistent Treatment 66 Š 2016 Alimera Sciences, All Rights Reserved6 Source: (a) OZURDEXŽ data from European Medicines Agency Assessment Report (b) ILUVIENŽ data from Phase III Clinical Trials (FAME)
- 7. Side effects of steroids are known ⢠ILUVIEN brings innovation to ophthalmology ⢠Side effects are mitigated by applying the lowest possible dose ⢠Real world evidence indicates our success 77 Š 2016 Alimera Sciences, All Rights Reserved7 HOWEVER ILUVIEN is not the steroid of yesterday
- 8. Location N° of eyes (pts) Follow-up IOP Change & management Medisoft 2nd data extract results (13 sites in the UK)1 290 Eyes (258 pts) Up to 763 days a. IOP elevation >30 mmHg, 6.6% b. Emergent IOP-lowering drops, 14.8% c. Rate of trabeculoplasty, 0% d. Rate of incisional surgery, 0% IRISS 2nd data extract (37 units in UK, DE, PT)2 328 Eyes (292 pts) Up to 763 days a. IOP elevation >30 mmHg, 8.2% b. Emergent IOP-lowering drops, 18.4% c. Rate of laser trabeculoplasty, 0% d. Rate of incisional surgery, 0.6% ILUVIEN Real-World Data Studies 1. Bailey C. Alimera Sciences symposium at EURETINA 2015. 2. Chakravarthy U. Alimera Sciences Advisory Board held on March 12 2016 in Paris, France.88 Š 2016 Alimera Sciences, All Rights Reserved8
- 9. 99 Š 2016 Alimera Sciences, All Rights Reserved9
- 10. Financial Overview As of 6/30/16 1010 Š 2016 Alimera Sciences, All Rights Reserved10 Q1 Q2 $7.2M U.S. $2.3M International $4.1M U.S. $1.7M International 2016 Revenue Growth (a) Includes Series A preferred stock and warrants, Series B preferred stock, common stock warrants, stock options and common stock. Q2 2016 Revenue $9.5M Q2 2016 Gross Margin 94.2% Q2 2016 Net Loss ($6.9M) Cash & Cash Equivalents* $42.0M Debt Outstanding $35M * The number shown for Cash & Cash Equivalents is a pro-forma representation including net cash raised of $25.4M in the Companyâs latest equity raise
- 11. Investor Presentation January 2015 OIS Presentation October 2016
Hinweis der Redaktion
- Contrast how chronic diseases are treated in other disease states versus DME Changed to yellow/blue in order to better flow through to next slide
- Continue to explain it with visual
- What are the three key goals to managing DME? Dry macula, check. Preservation of vision or improving sight, check. Reduction in burden of injections, check. Reduction in adverse events, herein lies the perception that ILUVIEN is an issue. We have eliminated 3, but we have a rep due to being a steroid
- This highlights how ILUVIEN works versus the others
- Take home Far right column, better outcomes than our approval studies (clinical trials) We now have had 4000 patients with almost no incisional surgery Take out columns 4/5 Contact column 4 Ken Green References 1. Dupas B et al. Alimera Sciences symposium at EURETINA 2015; 2. Figueira J et al ARVO 2016: poster #3257; 3. Bailey C. Alimera Sciences symposium at EURETINA 2015; 4. Bailey et al RCOphth 2016: poster #101. 5. Chakravarthy U. Alimera Sciences advisory board held on March 12 2016 in Paris, France. 6. Taylor et al RCOphth 2016: poster #110. Massin trial treatment groups Two groups were defined in advance: Group 1 included patients having received previous treatment in the study eye with laser photocoagulation for DME at least 3 months prior to the screening visit and no previous treatment with intraocular anti-VEGF therapy (anti-VEGF considered inappropriate); Group 2 included patients previously treated in the study eye with laser photocoagulation for DME, including focal/grid and pan-retinal, at least 3 months prior to the screening visit and with past history of âĽ3 monthly anti-VEGF treatments.
- In fact we have three prominent US physicians presenting on the concept on Sunday.